Insights
Insights From Our Experts
Articles
IDN Trends, Insights and Strategies Every Manufacturer Should Know
In this latest webinar, hear from three industry experts as the delve into the intricacies of integrated delivery networks (IDNs) and how they are transforming the healthcare landscape. EVERSANA’s Faruk Abdullah and Krista Pinto, and Matthew…
Clinical Data Portability for Regulatory Submissions Across Global Markets
Navigating the regulatory landscape for medical devices is complex, especially in relation to using clinical study data from overseas to support regulatory approval and reimbursement in the U.S., EU and U.K. The key question many companies…
Understanding IDNs and What They Mean to the Pharmaceutical Industry–Q&A with Greg Skalicky
Integrated Delivery Networks have impacted everything from drug launches to sales approaches. Integrated Delivery Networks have changed the healthcare landscape over the past decade. Greg Skalicky, President at EVERSANA, spoke with Pharmaceutical Executive about the ways…
EVERSANA’s Commitment to Health Innovation in Europe: Leading the Charge at Frontiers Health 2024
EVERSANA is leading conversations about next-generation commercialization as the presenting sponsor at the global health innovation event Frontiers Health 2024. As we expand our global reach in Europe and beyond, Frontiers Health represents the perfect event…
Budget Impact Analysis of Minimally Invasive Versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease in Europe
When traditional therapies fail to provide relief from pain caused by lumbar degenerative diseases, surgical approaches such as transforaminal lumbar interbody fusion (TLIF) may be used. TLIF can be performed using traditional open techniques (O-TLIF) or…
A Matching-Adjusted Indirect Comparison (MAIC) of Guselkumab Versus Risankizumab in Patients With Moderate-to-Severe Plaque Psoriasis
Psoriasis (PsO) patients have multiple biologic treatments to choose from, including the interleukin-23 inhibitors guselkumab and risankizumab. Both have demonstrated superior skin efficacy, as assessed using Psoriasis Area and Severity Index (PASI) scores, in their respective…
Evolving Standards: NICE’s Enhanced RWE Framework for Global Data Transportability
The National Institute for Health and Care Excellence (NICE) has updated its real-world evidence (RWE) framework published in June 2022. The framework guides the planning, conduct and reporting of RWE studies, with the objective of improving…
AI’s Role in Drug Launches, Operations, and Drug Pricing: Q&A with Abid Rahman
Over the past year, AI-powered technology has become more and more commonplace across the pharmaceutical industry. Abid Rahman, senior vice president of innovation at EVERSANA, spoke with Pharmaceutical Executive about some of the various sectors where…
Filling in the Gaps: Predicting Treatment Effects From Surrogate Endpoints
Over the past 15 years, the treatment landscape for first-line metastatic castration-resistant prostate cancer (mCRPC) has undergone significant changes, marked by the approval and investigation of several new therapies. With multiple pharmacological treatments available for first-line…
In-Depth with an Industry Leader: Global Launch Ambitions and Paradigm Shifts
Biotech enterprises, driven by the dual goals of treating a maximum patient population and ensuring a robust return on investment, must strategically navigate the complex landscape of global commercialization. Although the United States remains a crucial…